Stereospecific antitumor activity of radicicol oxime derivatives

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 6, 2001, Pages 435-445

  Soga, S ^a   Sharma, S V ^a   Shiotsu, Y ^a   Shimizu, M ^a   Tahara, H ^a   Yamaguchi, K ^a   Ikuina, Y ^a   Murakata, C ^a   Tamaoki, T ^a   Kurebayashi, J ^a   Schulte, T W ^a   Neckers, L M ^a   Akinaga, S ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Apoptosis; Breast cancer; erbB2; Hsp90; Radicicol

Indexed keywords

6 O [2 (2 PYRROLIDONYL)ETHYL]RADICICOL OXIME; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; KF 55823; KF 58332; KF 58333; OXIME DERIVATIVE; PROTEIN; RADICICOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; STEREOISOMERISM; STEREOSPECIFICITY; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; GENES, ERBB-2; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INJECTIONS, INTRAVENOUS; LACTONES; MACROLIDES; MICE; MICE, INBRED BALB C; MICE, NUDE; OXIMES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0035206178     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100373     Document Type: Article

References (39)

1. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma
2. Hsp90 & co. - A holding for folding
3. erbB2
4. The 90-kDa molecular chaperone family: Structure, function, and clinical applications. A comprehensive review
5. Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction
6. PC3 human prostate xenograft retention of, and oncoprotein modulation by, 17-allylaminogeldanamycin (17-AAG) in vivo
7. Protocols for screening chemical agents and natural products against animal tumors and other biological systems
8. Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells
9. Functional requirement of p23 and Hsp90 in telomerase complexes
10. Inhibition of signal transduction by the hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis
11. Establishment and characterization of a cell line of human breast carcinoma origin
12. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
13. A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice
14. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6
15. Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer
16. Molecular chaperones: The busy life of Hsp90
17. Hypoxia-induced activation of HIF-1: Role of HIF-1alpha-Hsp90 interaction
18. Accelerated degradation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells
19. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 function and the hsp90 association
20. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity
21. Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis
22. The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors
23. Steroid receptor interactions with heat shock protein and immunophilin chaperones
24. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
25. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for her2 overexpression metastatic breast cancer (HER2 + MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
26. The Hsp90 complex - A super-chaperone machine as a novel drug target
27. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway
28. The antibiotic radicicol binds to the N-terminal domain of HSP90 and shares important biologic activities with geldanamycin
29. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones
30. HER2 signal transduction in breast cancer cells
31. Specific changes in rasGAP-associated 62 kilodalton protein during integrin mediated cell-substrate interaction
32. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, Radicicol
33. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex
34. Molecular chaperones: Biology and prospects for pharmacological intervention
35. Radicicol leads to selective deletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway
36. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules
37. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
38. Heat-shock protein 90 governs the activity of pp60v-src kinase
39. The hsp90 chaperone system as a potential therapeutic target: Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases